search

Active clinical trials for "Sclerosis"

Results 2751-2760 of 3381

Adherence in Pediatric Multiple Sclerosis

Multiple Sclerosis

Disease modifying therapies (DMT) are widely used for children and adolescents with MS. Nonetheless, many pediatric patients continue to relapse and therefore require changes in therapy. We designed this research study to learn more about medication use in children and adolescents with MS. We are also interested in learning what a behavioral feedback intervention can tell us about adherence to medicine. Finally, we hope this research project will inform the way we provide clinical care for children and adolescents with MS.

Completed6 enrollment criteria

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya...

Multiple Sclerosis-Relapsing-Remitting

This study will determine whether in RRMS patients receiving Gilenya there is a link between disease progression and biologic markers.

Completed8 enrollment criteria

sCD163 in ALS Patients

Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a fatal disease with progressive muscle weakness leading to severe disability and eventually death.Since the diagnosis relies on clinical features and electromyographic abnormalities, which may occur rather late in the disease course, there is a need to identify diagnostic tests that can confirm or exclude the diagnosis of ALS in the earlier phase of the disease. More recently, there are studies suggesting neuroinflammation to play a role for the development of ALS. Cluster of differentiation 163 is found to be up regulated in a large range of inflammatory diseases. At the investigators lab, pilot data (Kallestrup M et al, unpublished data) has shown promising results. There was an increased level of cluster of differentiation 163 (sCD163) in cerebrospinal fluid in 7 patients with ALS compared with controls. The purpose of the investigators study is to define the concentration of sCD163 in the cerebrospinal fluid and serum in patients with ALS compared with controls (patients with unspecified neurological symptoms). Furthermore, the investigators will define the concentrations of protein, glucose, immunoglobulin G index and other factors in the spinal fluid.

Completed3 enrollment criteria

Long-term Follow-up of Fingolimod Phase II Study Patients

Multiple SclerosisRelapsing Forms of Multiple Sclerosis

This study collected follow-up data on approximately 90% of participants who were randomized and received one dose of study drug in FTY720D2201 (D2201). No study drug was given or required. Participants were required to be assessed at one or two visits, preferably at the original study site, but the option to be interviewed via phone or seen at home was provided. Information was gathered also on deceased participants. Assessments were performed only once within an 8 week period and included medical history, Multiple Sclerosis (MS) and Multiple Sclerosis Disease Modifying Therapy (MS DMT) history, Expanded Disability Status Scale (EDSS), Magnetic Resonance Imaging (MRI), and Multiple Sclerosis Functional Composite (MSFC).

Completed3 enrollment criteria

Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif

Multiple Sclerosis

The purpose of this study is to determine whether Rebif has an impact on employment status, quality of life and cognition.

Completed9 enrollment criteria

Walking With FES or AFO in People With MS With Foot Drop

Multiple SclerosisFoot Drop

This investigation consists of two parallel groups of participants who will follow the same protocol. The aim of the study is to investigate the effects of using Functional Electrical Stimulation/Ankle Foot Orthosis (AFO) or splint as an assistive mobility device over a 12 week period in people with MS who experience foot drop. Patients who are clinically prescribed FES will be invited to participate in the FES arm of the study. Patients who are clinically prescribed an AFO will be invited to participate in the AFO arm. Participants will be asked to make four visits to the gait laboratory at Queen Margaret University. Four weeks before the start of device use (Baseline - 4 weeks), start of device use (Baseline), after 6 weeks and 12 weeks of device use. Participants' walking will assessed using computerised three dimensional motion analysis, which will provide a detailed description of the movements (kinematics) of the lower limbs. Participants will also be asked to carry out a 10 metre walk and a two minute walk. Both gait analysis and the walking performance tests will be carried out with and without an assistive device; apart from their first session where participants will only be assessed without their assistive device. Participants will be asked to wear an activity monitor for 7 days after each assessment. In addition participants will be asked to complete four short standardised questionnaires (MS walking scale, MS impact scale (MSIS-29), Fatigue severity score and the Leeds MS Quality of life score) at each assessment.

Completed6 enrollment criteria

Study of Electrical Impedance Myography (EIM) in ALS

Amyotrophic Lateral SclerosisMotor Neuron Disease2 more

This trial is studying Electrical Impedance Myography (EIM) for measuring muscle health. The trial is studying people with Amyotrophic Lateral Sclerosis (ALS), other neuromuscular diseases, and healthy volunteers to see if the EIM device can measure disease in muscle tissue.

Completed22 enrollment criteria

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

Multiple Sclerosis

This study is designed to evaluate the effect of Tysabri on cognition in multiple sclerosis (MS) patients. During a period of 24 months, the study will assess the evolution of cognitive function in Tysabri treated MS patients using the Symbol Digit Modalities Test (SDMT) and the CogState battery of tests.

Completed3 enrollment criteria

A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years

Multiple Sclerosis

The primary aim of this study is to evaluate the effect of using Tysabri on changes in the brain using MRI and on disease progression in patients with relapsing-remitting Multiple Sclerosis over 5 years.

Completed14 enrollment criteria

Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns

Multiple SclerosisUrinary Bladder Diseases

This study will assess the impact of a systematic bladder health screening and disease education regimen as well as the implementation of a referral process on the quality of life of multiple sclerosis patients with bladder dysfunction.

Completed2 enrollment criteria
1...275276277...339

Need Help? Contact our team!


We'll reach out to this number within 24 hrs